LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violati
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“
NEW YORK--(BUSINESS WIRE)---- $QURE #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQURE N.V. (“uniQURE” or the “Company”) (NASDAQ:
LOS ANGELES , Nov. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQ
LOS ANGELES , Nov. 11, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violatio
RADNOR, Pa. , Nov. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf o
UniQure stock is rated a Buy with a $66 price target, offering upside after recent FDA pushback on AMT-130 Huntington's therapy trial design. AMT-130 is the first disease-modifying therapy for Hunting
uniQure N.V. ( QURE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi
uniQure (QURE) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.91 per share a year ago.
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington's disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progre
~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~
uniQure disclosed the FDA no longer agrees its AMT-130 trial data may support a BLA submission, making timing unclear. Shares fell over 57% on the news.
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE). The investig
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE